Send to

Choose Destination
Semin Hematol. 2011 Jul;48(3):227-39. doi: 10.1053/j.seminhematol.2011.03.009.

Allogeneic stem cell transplantation in mantle cell lymphoma: where are we now and which way should we go?

Author information

Service d'hématologie clinique du CHU de Nantes, Nantes, France.


Despite the use of intensive chemotherapy regimens with or without autologous stem cell transplant (auto-SCT) support, the clinical course of mantle cell lymphoma (MCL) remains characterized by iterative relapses and is still an incurable disease. The impact of allogeneic stem cell transplantation (allo-SCT) in MCL emerged in the late 1990s when it was shown that myeloablative allo-SCT could potentially cure some relapsed/refractory MCL patients. This curative impact is sustained by a graft-versus-disease (GVD-MCL) effect. However, toxicity and mortality following myeloablative allo-SCT are too high and have limited its use for patients aged under 65 years at diagnosis. Reduced-intensity conditioning regimens (RIC-allo) entail lower toxicity and reduced transplant-related mortality (TRM), making allogeneic transplant a valid option for a larger MCL population. At present, RIC-allo should be considered a valid therapeutic option for relapsed MCL patients and innovative therapeutic strategies including RIC-allo need to be investigated. Herein, the role of GVD-MCL and place of allo-SCT in MCL is discussed, taking into account the most recent literature, and several ways to improve RIC-allo in MCL that deserve to be explored are presented.

[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center